A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.
Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.
Click here to read a recent International Union Against Tuberculosis and Lung Disease Editorial by RESIST-TB members, Sarah McAnaw, Carole Mitnick, and Bob Horsburgh.
“New treatments for a serious disease generate understandable excitement among patients with life-threatening conditions. As pharmaceutical companies consider compassionate use of experimental drugs, one factor is commonly cited as a barrier to such use: fear that adverse events incurred by patients during Compassionate Use/Expanded Access (CU/EA) will impede regulatory approval of the drug. Such concerns stem from the obligation to report adverse events—that are serious, unexpected, and suspected to be related to the investigational drug— experienced by patients during treatment under CU/ EA programs.1 Such reports, it is feared, will damage the future of the drug, particularly since adverse events may not be related to the experimental drug and patients taking such drugs are typically sicker than the average patient.2 Existing evidence, however, does not support the notion that such events jeopardize regulatory approval.” Click here to read the article in full.
Recent News and Announcements
“The emergence of drug-resistant TB is a major global health concern, which threatens the ambitious goals and progress set under the End TB Strategy. Isoniazid-resistant TB, which is present in 8% of TB cases worldwide, reduces treatment success in patients treated with the standard 6-month first-line regimen. The new WHO recommendations for the treatment of […]
DR-TB STAT + TAG brief: Is Shorter Better? Understanding the Shorter Regimen For Treating Drug-Resistant Tuberculosis “Multidrug-resistant TB (MDR-TB) is a growing problem around the world, and is difficult to treat. In 2016, the World Health Organization (WHO) recommended a shorter regimen for treating MDR-TB. Now, data from a randomized controlled trial are available. The […]
New trial evaluates whether the efficacy of the BPaL drug regimen can be maintained with reduced toxicity “TB Alliance has announced the start of a clinical trial of a three-drug regimen to treat extensively drug resistant tuberculosis (XDR-TB)—one of the deadliest forms of tuberculosis (TB)—and those with pre-XDR-TB and multi-drug resident TB (MDR-TB) whose prior […]
This Position Statement by the World Health Organization (WHO) on the use of delamanid in the treatment of multidrug-resistant tuberculosis (MDR-TB) has been developed in response to the final data from the phase III, multicentre, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of delamanid (Trial #242-09-213, hereafter referred to as ‘Trial […]
On Thursday, January 25th from 08:00 – 09:00 EST (14:00 – 15:00 CET; 15:00 – 16:00 SAST) Dr. Susan van den Hof presented on KNCV’s Patient Triage Approach. KNCV Tuberculosis Foundation developed the Patient Triage Concept to ensure rapid diagnosis of TB and all forms of DR-TB (i.e. using rapid diagnostics) followed by early initiation of the […]